Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks

Pellicano, F. and Holyoake, T.L. (2011) Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. Journal of Experimental Medicine, 208(11), pp. 2155-2158. (doi: 10.1084/jem.20112087)

Abstract

The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors (TFs). B cell lymphoma 6 (BCL6) is a transcriptional repressor whose translocation or mutation is associated with diffuse large BCL. New data now show that BCL6 is critical for the maintenance of leukemias driven by the BCR-ABL translocation (Philadelphia chromosome), suggesting that BCL6 is a novel, targetable member of the complex signaling pathways critical for leukemic stem cell survival.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Holyoake, Professor Tessa and Pellicano, Dr Francesca
• Authors: Pellicano, F., and Holyoake, T.L.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: Journal of Experimental Medicine
• Publisher: Rockefeller University Press
• ISSN: 0022-1007
• ISSN (Online): 1540-9538
• Published Online: 24 October 2011
• Copyright Holders: Copyright © 2011 The Authors
• First Published: First published in Journal of Experimental Medicine 208(11):2155-2158
• Publisher Policy: Reproduced in accordance with the copyright policy of the publisher